Skip to content

Translational study of the patented perioperative immunomodulatory drug Qi-Zhu-Fang in Gu's surgery for malignant tumours

Translational study of the patented perioperative immunomodulatory drug Qi-Zhu-Fang in Gu's surgery for malignant tumours

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025001061
Enrollment
Unknown
Registered
2025-05-28
Start date
2025-03-26
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 4.1 Age =18 and =75 years old gender is not limited; 4.2 Patients with a clear pathological diagnosis of breast cancer/thyroid cancer/lung cancer who have completed a standard mastectomy/lobectomy or anatomical pneumonectomy/thyroidectomy at Yueyang Hospital on the same day; 4.3 Chinese medicine diagnosis and typing of Qi deficiency and blood stasis; 4.4 Patients who have been treated with Astragalus Formula for =14 days since the first day of surgery or who have not been treated with Astragalus Formula since the first day of surgery; 4.5 Complete contact information medical history and other relevant information; 4.6 Those who understand and agree to participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 5.1 Patients with a combination of serious primary diseases of the liver kidneys haematological system or other serious infectious diseases who in the opinion of the investigator suffer from serious diseases of other systems that would affect the judgement of the results of this study; 5.2 Patients with a combination of other primary tumours; 5.3 Comorbid psychiatric illnesses such as mania schizophrenia or other reasons for not being able to co-operate with the observational study; 5.4 Patients with pre-existing distant metastases of malignant tumours.

Design outcomes

Primary

MeasureTime frame
Days in hospital;Postoperative complication rate;Time to first bedside mobility;

Secondary

MeasureTime frame
Blood Immunity Indicators;Incidence of tumour-related surgical complications;Revised Piper Fatigue Scale;channel traffic;EORTC QLQ-C30;Perioperative fever and antibiotic use;Perioperative pain and analgesic use;Recurrence-free survival;Extraction time;Chinese Medicine Symptoms Score;

Countries

china

Contacts

Public Contactshengjiayu

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

sjy1983sh@126.com13361990930

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026